Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan

被引：0
作者：
Djalila Mekahli
Lisa M. Guay-Woodford
Melissa A. Cadnapaphornchai
Stuart L. Goldstein
Ann Dandurand
Huan Jiang
Pravin Jadhav
Laurie Debuque
机构：
[1] KU Leuven,PKD Research Group, Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine
[2] University Hospital of Leuven,Department of Pediatric Nephrology
[3] Children’s National Research Institute,Center for Translational Research
[4] Rocky Mountain Hospital for Children at Presbyterian/St. Luke’s Medical Center,Rocky Mountain Pediatric Kidney Center
[5] University of Cincinnati School of Medicine,Center for Acute Care Nephrology, Cincinnati Children’s Hospital Medical Center
[6] Cerevel Therapeutics,undefined
[7] Otsuka Pharmaceutical Development & Commercialization,undefined
[8] Inc.,undefined
[9] MDCI Biosciences LLC,undefined
来源：
Pediatric Nephrology | 2024年 / 39卷
关键词：
Autosomal dominant polycystic kidney disease; ADPKD; Chronic kidney disease; Risk assessment; Kidney volume; Pediatric; Tolvaptan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1481 / 1490
页数：9
相关论文
共 194 条
[91]  
Bae KT(undefined)undefined undefined undefined undefined-undefined
[92]  
Hogan M(undefined)undefined undefined undefined undefined-undefined
[93]  
Miskulin D(undefined)undefined undefined undefined undefined-undefined
[94]  
Chonchol M(undefined)undefined undefined undefined undefined-undefined
[95]  
Zheng D(undefined)undefined undefined undefined undefined-undefined
[96]  
Wolfe M(undefined)undefined undefined undefined undefined-undefined
[97]  
Cowley BD(undefined)undefined undefined undefined undefined-undefined
[98]  
Wallace DP(undefined)undefined undefined undefined undefined-undefined
[99]  
Yamaguchi T(undefined)undefined undefined undefined undefined-undefined
[100]  
Grantham JJ(undefined)undefined undefined undefined undefined-undefined
567891011121314